Defunct Company
Total Trials
11
As Lead Sponsor
8
As Collaborator
3
Total Enrollment
3,487
NCT00638365
Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas Aeruginosa
Phase: Phase 1/2
Role: Lead Sponsor
Start: Mar 31, 2008
Completion: Apr 30, 2009
NCT00691587
Pilot Trial of KB001 in Mechanically-Ventilated Patients Colonized With Pseudomonas Aeruginosa
Start: Apr 30, 2008
NCT00995449
Study of KB003 In Biologics-Inadequate Rheumatoid Arthritis
Phase: Phase 2
Start: Jan 31, 2010
Completion: Feb 29, 2012
NCT01211691
Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)
Start: Sep 30, 2010
Completion: Dec 31, 2016
NCT01603277
Effect of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids
Start: Jul 31, 2012
Completion: Jan 31, 2014
NCT01695343
Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment
Start: Dec 31, 2012
Completion: Dec 31, 2014
NCT02459171
Household Transmission of Zoonotic Influenza Viruses in a Cohort of Egyptian Poultry Growers
Phase: N/A
Role: Collaborator
Start: Aug 5, 2015
Completion: Apr 23, 2022
NCT02546284
Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)
Phase: Phase 1
Start: Jul 31, 2016
Completion: Feb 29, 2020
NCT03374943
A Trial of KB004 in Patients With Glioblastoma
Start: Dec 5, 2017
Completion: Sep 22, 2021
NCT04351152
Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19
Phase: Phase 3
Start: May 5, 2020
Completion: Mar 31, 2021
NCT04314843
Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma
Start: May 26, 2020
Completion: Jul 27, 2022